Tag Archives: IRWD

Best Growth Stocks For 2019

After a brutal two months for all things retail, especially those in the athletic footwear space, the long awaited Nike (NYSE:NKE) earnings have just been reported and they have some extreme implications for names like Foot Locker (NYSE:FL) and The Finish Line (FINL). I have opined that Nike is a buy in that past the closer it gets to $50, and have been buying Foot Locker since it fell well under $60, and completing my position in the mid-$40s. That said, does my buy call hold water for Nike? Let us turn to the earnings, where we see that Nike just delivered a pretty strong quarter.

What do I mean? Well, Nike just reported a Q4 that was a positive surprise, not unlike some other niche companies that have reported thus far. Let us remember that consensus estimates for Nike were to report revenues of $8.63 billion, earnings of $0.50 and gross profit margin of 44.3%.This is the benchmark. This quarter should have seen some benefits of the so-called delayed tax refunds that many companies cited in their Q1 reports. Well, with its strong name brand and sales strategy, this was another decent quarter. It wasn’t perfect, but it was truly solid. Diluted earnings per share were up 22% year-over-year and beat by a whopping $0.10, coming in at $0.6. Continued strong international momentum drove better revenues and expenses were once again well managed. The revenue growth was clear. Revenues rose 5% year-over-year to $8.7 billion and up 7% in constant dollars. This figure met expectations of the Street. It was a solid performance, but we need to dig further.

Best Growth Stocks For 2019: ENERGY TRANSFER PARTNERS(ETP)

Advisors’ Opinion:

  • [By ]

    That, by itself, doesn’t mean their dividends are on solid ground. However, Energy Transfer Partners (NYSE: ETP) deserves a closer look. Like many master limited partnerships (MLPs), it has pulled back over the past week because of a new ruling from the Federal Energy Regulatory Commission (FERC), which regulates tariffs on interstate pipelines.

  • [By Max Byerly]

    Energy Transfer Partners LP (NYSE:ETP) has earned an average recommendation of “Hold” from the fifteen research firms that are covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and eight have given a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $23.60.

  • [By Matthew DiLallo]

    After lots of analysis and discussion, Energy Transfer Equity recently announced that it has agreed to merge with its MLP Energy Transfer Partners (NYSE:ETP) in a $27 billion deal that will create a nearly $100 billion energy infrastructure behemoth. In addition to increasing the size and scale of the company, several other reasons were highlighted by CFO Tom Long about why the company is happy to finally be able to announce this transaction: 

  • [By Matthew DiLallo]

    Because Magellan Midstream Partners has lived within its means over the past five years, the average number of units it has outstanding is up less than 1%. Contrast that with rivals Buckeye Partners (NYSE:BPL) and Energy Transfer Partners (NYSE:ETP), which have a much more aggressive approach to financing growth because they typically pay out virtually all their cash flow to investors each quarter. That forced both to issue a boatload of new equity and debt to fund acquisitions and expansion projects. As a result, Buckeye’s outstanding unit count has surged 41%, while Energy Transfer’s is up a jaw-dropping 120% over the past five years.

Best Growth Stocks For 2019: Ironwood Pharmaceuticals Inc.(IRWD)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Ironwood Pharmaceuticals (NASDAQ:IRWD) and GTX (NASDAQ:GTXI) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends.

  • [By Motley Fool Transcribers]

    Ironwood Pharmaceuticals Inc  (NASDAQ:IRWD)Q4 2018 Earnings Conference CallFeb. 13, 2019, 8:30 a.m. ET

    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:


  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Ironwood Pharmaceuticals (IRWD)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Todd Campbell]

    After reporting fourth-quarter financial results that were better than expected on both the top and bottom line and updating investors on its plans to split into two companies, Ironwood Pharmaceuticals (NASDAQ:IRWD) surged 11.7% higher today.

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Ironwood Pharmaceuticals (IRWD)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Best Growth Stocks For 2019: YPF Sociedad Anonima(YPF)

Advisors’ Opinion:

  • [By Shane Hupp]

    YPF (NYSE:YPF) and HollyFrontier (NYSE:HFC) are both oils/energy companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on YPF (YPF)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on YPF (YPF)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Rich Smith]

    YPF SA (NYSE:YPF) produces oil and gas — and also lives in Buenos Aires.

    And Mercadolibre (NASDAQ:MELI) — probably the best-known name on this list — is the Latin American equivalent of eBay here in the U.S. And yes, you guessed it — Mercadolibre is headquartered in Buenos Aires as well.

Your Daily Pharma Scoop: IRWD Division, Jazz sNDA, Siga Adcomm

Analysis focus: IRWD

Ironwood Pharma (NASDAQ:IRWD) is going to split into two separate companies, both publicly traded, with one focusing on commercialization and the other on R&D. This move will happen in the first half of 2019 and be tax free to current shareholders.

Ironwoods linzess, which was approved 6 years ago in irritable bowel syndrome with constipation and for treatment of chronic idiopathic constipation. Recently, as we know, Synergy Pharmas (NASDAQ:SGYP) Trulance got approved by the FDA for the same indications. Now, according to some sources, Trulance is a safer drug than Linzess. However, Trulance has not been able to take off as well as investors had assumed, although it has put a dent in the prospects of Linzess.

Linzess is marketed by Allergan (NYSE:AGN), which has considerable marketing prowess. Now, this bid to separate IRWD into two divisions probably owes itself to one reason – that after 6 years of approval, IRWD has still not been able to become profitable. As the announcement of this news says, the commercial division of IRWD, which is focused on Linzess, ..is expected to be profitable in 2019. That means, if you reduce the R&D expenses from the total cash burn of the company, then it could become profitable on Linzess revenues. At least, that seems to be the idea.

The other division will do R&D on cyclic guanosine monophosphate pharmacology to advance a pipeline of treatments for rare and serious diseases led by mid-stage candidates praliciguat and olinciguat. This will be the division that will look for future treatments to bring to market as Linzess completes its market cycle.

For SGYP investors, what is interesting to note here is that this move seems aimed to make Linzess profitable for at least a part of the company. That is to say, the old Ironwood has to shed the more cash burning part of it – the R&D section – to make this happen.

This could mean, either, that Trulance is really taking over some of Linzess traditional market, and/or the market itself is not sustaining enough for Linzess to make enough money to cover Ironwoods entire cash requirements, although IRWD has managed to reduce OpEx drastically.

The first idea is a good thing for Synergy investors; the second is a sobering conclusion of how just getting a product approved but without proper money and marketing management can still ruin the future prospects of a company.

In related news, IRWD released earnings results for Q1 and missed both by EPS and by revenue, despite seeing a 32% increase in revenue Y/Y.

Stocks in News: Analysis of JAZZ, SIGA

Jazz Pharma submits U.S. marketing application for expanded use of Xyrem

Discussion: Jazz Pharmas (NASDAQ:JAZZ) Xyrem was first approved in 2002 to treat cataplexy in narcolepsy and for EDS in narcolepsy. This expanded use sNDA will increase the scope of Xyrem to include pediatric patients. The market isnt much because Age of onset for narcolepsy typically occurs in the second decade of life; however, diagnosis can occur 1016 years later on average.

FDA Ad Com backs SIGA’s smallpox treatment

Discussion: Naturally occuring smallpox was eradicated in 1980, but SIGA technologies (NASDAQ:SIGA) TPOXX (tecovirimat) is an antiviral oral treatment targeting smallpox when used as a biological weapon, for which no medicine exists as of now. Vaccination is risky and not efficient for people with low exposure risks, especially for an eradicated disease. However, the market for this new drug candidate will be for defense purposes. PDUFA is August 8.

In other news

Karyopharm (NASDAQ:KPTI), which was highlighted in yesterdays scoop, has now come up with a $125mn stock offering, taking the stock down 3%.

Mallinckrodts (NYSE:MNK) stannsoporfin has an adcomm on Thursday for elevated blood bilirubin in neonates (at least 35 weeks’ gestational age) with indicators of hemolysis (rupture of red blood cells) who are at risk of developing severe hyperbilirubinemia (excess bilirubin in the blood). This is a small market.

Medtronics (NYSE:MDT) Deep Brain Stimulation therapy has been approved by the FDA as adjunctive therapy for adult patients with partial onset seizues in drug resistant epilepsy.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.